| Aberrant expression of B203.13 antigen in acute lymphoid leukemia of B-cell origin |
Authors: Giuliana Gobbi, Prisco Mirandola, Chiara Malinverno, Ivonne Sponzilli, Cecilia Carubbi, Francesca Ricci, Roberto Binazzi, Giuseppe Basso, Gabriella Giuliani-Piccari, Giulia Ramazzotti, Guido Pasquantonio, Lucio Cocco, Marco Vitale |
Affiliations:
Department of Anatomy, Pharmacology and Forensic Medicine, Human Anatomy Section, University of Parma, Ospedale Maggiore, I-43100 Parma, Italy
|
Pages: 371-374 |
Abstract:
The B203.13 monoclonal antibody was developed by immunizing mice with the B/monocyte biphenotypic cell line B1b. During normal hematopoiesis B203.13 is expressed on a fraction of CD34+ cells, while on mature cells it is only present on B-lymphocytes. We tested this antibody as a marker of childhood B-acute lymphoblastic leukemia (B-ALL). Bone marrow aspirates from 139 cases of early B-ALL and 25 controls were studied. About 40% of the B-ALL patients expressed B203.13. In these patients, B203.13 was constantly co-expressed with CD10, but never co-expressed with CD20, contrary to the controls. The CD10+/B203.13+ phenotype was specific to B-ALL, since CD10+/CD20+ cells from common acute lymphoblastic leukemia (c-ALL) did not express B203.13. We concluded that the use of B203.13 in association with CD10 and CD20 provides meaningful information for distinguishing normal residual B-cells from leukemic B-lymphoblasts and that recurrence of a CD10+/B203.13+ phenotype after transplantation may be a very early relapse indicator of early B-acute lymphoblastic leukemia.
|
|
|
|
|
